Y-mAbs Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2015-04-01
- Employees
- 100
- Market Cap
- $676.1M
- Website
- http://www.ymabs.com
- Introduction
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in Ne...
Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT05994157
- Locations
- ๐บ๐ธ
HonorHealth, Scottsdale, Arizona, United States
๐บ๐ธCity of Hope, Duarte, California, United States
๐บ๐ธCorewell Health-BAMF Health, Grand Rapids, Michigan, United States
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
- Conditions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT05130255
- Locations
- ๐บ๐ธ
Corewell Health-BAMF Health, Grand Rapids, Michigan, United States
๐บ๐ธMemorial Sloan- Kettering Cancer Center, New York, New York, United States
๐บ๐ธHonorHealth, Scottsdale, Arizona, United States
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT05077423
- Locations
- ๐บ๐ธ
Washington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธUPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
๐บ๐ธUniversity of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT05063357
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT04909515
- Locations
- ๐ท๐บ
National Medical Research Center Pediatric Hematology, Oncology and Immunology n.a Dmitry Rogachev, Moscow, Russian Federation
๐ธ๐ฌICON Cancer Centre Novena, Singapore, Singapore
๐ท๐บResearch Institute of Pediatric Oncology ad Hematology of N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT04750239
- Locations
- ๐บ๐ธ
Washington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT04560166
- Locations
- ๐ฐ๐ท
Asan Medical Center Children's Hospital, Seoul, Korea, Republic of
๐ฐ๐ทSeoul National University Hospital, Seoul, Korea, Republic of
๐ญ๐ฐHong Kong Children's Hospital, Hong Kong, Hong Kong
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
- Conditions
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT04315246
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธDuke Cancer Center, Durham, North Carolina, United States
๐ฌ๐งThe Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT04167618
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธDoernbecher Children's Hospital, Portland, Oregon, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT03860207
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States